onc Videos

Videos

Conference Coverage

Treatment Strategies for Patients With Double Refractory Chronic Lymphocytic Leukemia

02/27/2024

Featuring Neil E. Kay, MD

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Neil E. Kay, MD, discusses the pathobiology and management of double refractory CLL.

At the Lymphoma, Leukemia &...

02/27/2024

Oncology

Andrew Zelenetz, MD, Memorial Sloan Kettering Cancer Center

Videos

Analyzing Immunotherapy Options for the Treatment of Patients With Large-Cell Lymphoma

02/26/2024

Featuring Andrew Zelenetz, MD

Andrew Zelenetz, MD, discusses up and coming treatment developments on the horizon within the large-cell lymphoma research space, focusing on the importance of immunotherapy.

Andrew Zelenetz, MD, discusses...

02/26/2024

Oncology

Videos

R-CHOP Followed by R-ICE Treatment Shows Potential for Patients With Non-GCB DLBCL

02/26/2024

Featuring Andrew Zelenetz, MD

Andrew Zelenetz, MD, shares study results that suggest sequential rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) induction followed by rituximab, ifosfamide, carboplatin, and etoposide ([R]-ICE) consolidation...

Andrew Zelenetz, MD, shares...

02/26/2024

Oncology

Conference Coverage

Optimal Use of Bispecific Antibodies for Multiple Myeloma Treatment

02/23/2024

Featuring Ajai Chari, MD

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, University of California – San Francisco, San Francisco, California, discusses the role of bispecific antibodies in the treatment of patients with multiple...

At the Lymphoma, Leukemia &...

02/23/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Evaluating the Potential Value of MRD as a Predictive Variable for Multiple Myeloma

02/23/2024

Featuring Ajai Chari, MD

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, evaluates the potential value of measurable residual disease as a predictive variable for multiple myeloma.

At the Lymphoma, Leukemia &...

02/23/2024

Lymphoma, Leukemia & Myeloma Network

Videos

Capivasertib Plus Palbociclib and Fulvestrant for HR-Positive, HER2-Negative Advanced Breast Cancer

02/23/2024

Featuring Komal Jhaveri, MD

Komal Jhaveri, MD, discusses results from the CAPItello-291 study, which led to the FDA approval of capivasertib plus fulvestrant for HR-positive, HER2-negative, advanced breast cancer harboring one or more PIK3CA/AKT1/PTEN alterations.

Komal Jhaveri, MD, discusses...

02/23/2024

Oncology

Conference Coverage

Role of CD38 Monoclonal Antibodies and Bispecific Antibodies in Treating Multiple Myeloma

02/23/2024

Featuring Ajai Chari, MD

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, shares his insights on the role of CD38 monoclonal antibodies and bispecific antibodies for the treatment of patients with multiple myeloma.

At the Lymphoma, Leukemia &...

02/23/2024

Lymphoma, Leukemia & Myeloma Network

Reshma Mahtani, DO; Terry Mamounas, MD; Jane Meisel, MD

Videos

Pertuzumab Plus Trastuzumab for Early-Stage HER2-Positive Breast Cancer

02/22/2024

Reshma Mahtani , DO;

Terry Mamounas , MD;

Jane Meisel , MD;

In this video, a panel of experts highlight 8-year updated results from the APHINITY trial and reflect on the progress that has been made in the setting of HER2-positive breast cancer.

In this video, a panel of...

02/22/2024

Oncology

Videos

Assessing Efficacy of Jaktinib Among Ruxolitinib-Intolerant Patients With Myelofibrosis

02/21/2024

Jie Jin , MD, PhD;

Jie Jin, MD, PhD, shares results from a phase 2 study that explored the efficacy of Janus kinase inhibitor jaktinib treatment for ruxolitinib-intolerant patients with myelofibrosis.

Jie Jin, MD, PhD, shares results...

02/21/2024

Oncology

Videos

Optimizing Treatment for Patients With High-Risk HER2-Positive Breast Cancer

02/21/2024

Reshma Mahtani , DO;

Terry Mamounas , MD;

Jane Meisel , MD;

In this video, our experts explore therapy options for patients with high-risk HER2-positive breast cancer, sharing their views on anthracycline-based therapies, neratinib, and immunotherapy for these patients, and discussing data from the...

In this video, our experts...

02/21/2024

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology